Market Overview

UPDATE: Canaccord Genuity Downgrades Vical Following Allovectin Failure

Share:
Related VICL
Benzinga's Top Initiations
5 Gainers And Losers In The Pre-Market Today

In a report published Tuesday, Canaccord Genuity analyst Ritu Baral downgraded Vical (NASDAQ: VICL) from Buy to Hold, and lowered the price target from $7.00 to $1.40.

In the report, Canaccord Genuity noted, “Lowering to HOLD, $1.40 target on Allovectin Ph3 failure and program halt. We still see blockbuster potential for the Astellas-partnered CMV franchise (ASP0113, f.k.a. CymVectin; TransVax) given unmet need. Our $1.40 target is based on a pNPV analysis.”

Vical closed on Monday at $1.53.

Latest Ratings for VICL

DateFirmActionFromTo
Jul 2016H.C. WainwrightAssumesBuy
Jun 2015Roth CapitalDowngradesBuyNeutral
Jun 2015HC WainwrightInitiates Coverage onBuy

View More Analyst Ratings for VICL
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Ritu BaralAnalyst Color Downgrades Analyst Ratings

 

Related Articles (VICL)

View Comments and Join the Discussion!